feeds

2018

This report presents the top-level overview of the drug phenomenon in the Netherlands, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Turkey, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Germany, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the overview of the drug phenomenon in France, covering drug supply, use and public health problems, as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large share of drug-related problems in some European prisons and appropriate responses are mostly lacking. This preliminary analysis is the outcome of a targeted rapid information assessment or ‘trendspotter’ study carried out by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) between August and December 2017.

2018

Benzodiazepines are a widely prescribed group of medicines with a range of clinical uses, including the treatment of anxiety and insomnia and the management of alcohol withdrawal. For a number of reasons this group of medicines are often misused by high-risk opioid users and are associated with morbidity and mortality among this group. This analysis considers the significance of this problem and its impact for the health and drug treatment of opioid users.

01.06.2018
2018

This week, EMCDDA Director Alexis Goosdeel and members of his staff have been visiting IN-Mouraria, a low-threshold harm-reduction centre based in Lisbon. In 2019, the centre will become a managing partner of one of the new drug consumption rooms (DCRs) to be implemented in the capital by the Lisbon Town Hall.

2018

Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a valuable tool for identifying trends and new threats. As part of its programme for developing and improving drug supply indicators, the EMCDDA has been expanding its monitoring to include measures of wider drug-related crime, including DRH. However, there appears to be a significant gap in the available European data on this topic.

25.05.2018
2018

An EMCDDA Paper released today provides an overview of the information available on drug-related homicide (DRH) in Europe. This first snapshot provides practitioners and policymakers with the current state of the art on this topic.

24.05.2018
2018

EMCDDA Director Alexis Goosdeel will today address the 38th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) taking place on 23 and 24 May in Bucharest. A key theme on the congress programme is the emergence of new psychoactive substances (NPS).

2018

What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA, present the evidence on active case finding as a key measure to diagnose communicable diseases early. The two agencies advise to actively offer testing for hepatitis B, hepatitis C and HIV to all people in prison and to conduct universal testing for tuberculosis at prison entry.

23.05.2018
2018

What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA present evidence on active case finding as a key measure to diagnose communicable diseases early. The publication is launched in the first Spring European Hepatitis-HIV Testing Week (18–25 May 2018).

23.05.2018
2018

What is the impact of cannabis use on driving? Do edible and smoked cannabis products affect drivers in the same way? These are among the questions addressed in a new policy briefing on cannabis and driving, published today.

2018

With cannabis use and policy evolving internationally, drug-impaired driving has become an increasingly relevant policy issue. This briefing aims to provide those concerned with policy developments in the field of cannabis with a brief overview of current knowledge and the latest developments in the area of driving.

15.05.2018
2018

EMCDDA Director Alexis Goosdeel will address a conference hosted by the Lithuanian Drug, Tobacco and Alcohol Control Department (NTAKD) in Vilnius today, as the organisation prepares to present a new strategy (2018–2028) to the Lithuanian parliament and government.

Dedicated to Lithuania’s drug policy review, with its human rights and health approach, the conference will underline the importance of a balanced and long-term drug policy, geared towards the creation of a healthy and safe society.

2018

This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.

2018

This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.

14.05.2018
2018

Today the European Union has decided to subject two new synthetic cannabinoids to control measures across the 28 Member States. The substances in question are ADB-CHMINACA and CUMYL-4CN-BINACA, which have been raising health concerns in Europe.

27.04.2018
2018

The European Drug Report 2018: Trends and Developments will be launched on 7 June in Brussels. Accompanying the report will be the 2018 Statistical Bulletin, and 30 Country Drug Reports, presenting summaries of national drug phenomena in the EU-28, Turkey and Norway.

2018

Darknet markets — also known as cryptomarkets — provide a largely anonymous platform for trading in a range of illicit goods and services. It is estimated that around two thirds of the offers on darknet markets are drug-related. Drug sales on these markets, although modest when compared to the overall retail drug market, are significant and appear to be expanding.  EU-based suppliers are important players in the darknet ecosystem, the evolution of which is shown in this timeline.

2018

For more than 20 years, the European information network on drugs and drug addiction (Reitox), has been the cornerstone of the European drug monitoring and reporting system, to which it contributes by collecting, analysing, interpreting and disseminating data at national level, as well as by defining the tools for monitoring. The EMCDDA 2025 strategy, endorsed in 2016, aims at contributing to a healthier and more secure Europe. In this context, Reitox is currently defining the new strategic goals for the network as a whole and how these will be operationalised and achieved.

13.04.2018
2018

Drugs and drug-related harms continue to challenge prison systems in Europe and interventions in this setting must be driven by evidence gathered through monitoring, data-collection and research. The remarks come in conclusions published by the World Health Organization Regional Office for Europe (WHO–Europe), in collaboration with Public Health England and the EMCDDA.

27.03.2018
2018

Today cannabis is sold openly in 573 ‘coffeeshops’ operating in 103 of the 380 municipalities in the Netherlands.

19.03.2018
2018

Facilitating evidence-based health decision-making among professionals, patients and policymakers will be just one of the issues discussed today by EMCDDA Director Alexis Goosdeel and Chief Executive Officer of the Cochrane Collaboration Mark Wilson.

16.03.2018
2018

A call for abstracts is now open for the 9th annual conference of the European Society for Prevention Research (EUSPR).

08.03.2018
2018

The Justice and Home Affairs Council has adopted today Council conclusions on alternatives to coercive sanctions for drug using offenders.

08.03.2018
2018

Together, we the Heads of EU agencies and Joint undertakings commit to zero tolerance towards sexual harassment and we cannot and will not accept harassment of any form in our agencies.

07.03.2018
2018

The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EU drugs agency (EMCDDA).

2018

The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in around 60 European cities and towns (hereinafter referred to as ‘cities’) to explore the drug-taking habits of those who live in them. The results provide a valuable snapshot of the drug flow through the cities involved, revealing marked geographical variations*.

2018

In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 19 December 2017.

Loading